5 terminated, 3 completed, 1 withdrawn. 7 Phase 1, 3 Phase 2.
By phase and status
Follow LMB-100: new trials by email Literature Review of LMB-100 trials Research Report on LMB-100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin - Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe) | Phase 1 | Withdrawn | National Cancer Institute (NCI) | | 2024-01-31 | 2024-02-02 |
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
LMB-100, ipilimumab, Diphenhydramine - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2021-06-11 | 2024-02-02 |
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
LMB-100, pembrolizumab, Mesothelin Expression - Lung Cancer, Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2019-09-11 | 2024-04-16 |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma | Phase 1 | Completed | National Cancer Institute (NCI) | 19 | 2019-08-29 | 2023-08-01 |
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
LMB-100, Pembrolizumab - Mesothelioma | Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2018-12-04 | 2021-12-02 |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
LMB-100, SEL-110 - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2018-02-28 | 2019-11-22 |
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
LMB-100, Nab-Paclitaxel, Mesothelin Expression - Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2016-08-03 | 2022-03-15 |
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
LMB-100, nab-paclitaxel - Mesothelioma | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2016-07-27 | 2022-08-23 |
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
RO6927005, gemcitabine, nab-paclitaxel - Cancer | Phase 1 | Terminated | Hoffmann-La Roche | 15 | 2014-12-01 | 2016-07-26 |
Conditions studied
Mesothelioma (4) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Lung Neoplasms (1) · Mesothelioma, Malignant (1) · Myeloproliferative Disorder, Chronic, with Eosinophilia (1) · Pancreatic Neoplasms (1) · Pleural Effusion, Malignant (1)
Sponsors
National Cancer Institute (NCI) (8) · Hoffmann-La Roche (1)
Countries
United States (9) · Canada (1) · Denmark (1) · France (1)
Top investigators
Raffit Hassan, M.D. (4) · Christine C Alewine, M.D. (2) · Azam Ghafoor, M.D. (1) · David S Schrump, M.D. (1)
Results publications
PMID 36208017, PMID 38706610, PMID 41425223
NIH funding
2014 (1)